An Open Label Extension Study of the Efficacy of MORAb-003
| Status: | Completed |
|---|---|
| Conditions: | Ovarian Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | November 2009 |
| End Date: | August 2013 |
An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects With Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
An open label extension of the MORAb-003-002 study in order to continue the active patients
in the MORAb-003-002 study on maintenance MORAb-003 infusions after the main study is
closed.
in the MORAb-003-002 study on maintenance MORAb-003 infusions after the main study is
closed.
Inclusion Criteria:
- Provision of Informed consent
- Subjects must have been enrolled in and have met the inclusion/exclusion criteria of
the MORAb-003-002 study.
- Subjects must have achieved a normalization of CA 125 levels and/or CR or PR (or
stable disease and an investigator's assessment of a clinical benefit) after
MORAb-003 in combination with standard chemotherapy and have not yet met the criteria
for disease progression during participation in the MORAb-003-002 study.
- Subjects must be currently receiving single-agent MORAb-003 maintenance therapy.
Exclusion Criteria:
- Subjects that discontinued the MORAb-003-002 study for any reason.
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials